Novo Nordisk Rise as Wegovy Wins US Liver Disease Approval
Novo Nordisk is making headlines again. We saw its shares rise after the FDA approved Wegovy for a serious liver condition called MASH, or metabolic dysfunction-associated steatohepatitis. This recent approval is significant since Wegovy, previously known for weight management, can now also treat adults with moderate to advanced liver fibrosis. The news sparked optimism in…